Register now to R3i !
Your login
Your password
Confirm your password
Your email
I agree to receive the R3i newsletter
The Initiative

Prof. Eric Bruckert

Prof. Eric Bruckert
Hôpital Pitié-Salpêtrière
Paris, France
Medical Doctor, University Professor
Post-Graduate Diploma in Physico-Chemistry applied to medicine,
Master in Human Biology, Inter-University Diploma in
“Methods and evaluation of medical education”,
University Diploma in Cardiac Ultrasonography
Medical Thesis 1986, PARIS VI
Endocrinologist 1993

Address : Pitié-Salpêtrière Hospital, 47-83 Boulevard de l’Hôpital,
75651 PARIS Cedex 13, France

Current position
  Professor of Endocrinology at the Medical University (Paris VI)
  Head of the Endocrinology & Metabolism Department (University Hospital Pitié-Salpêtrière)
  Member of the Research center INSERM U551 (Director, MJ Chapman, Pitié-Salpêtrière Hospital)
  Member of the ICAN (Institute of Cardiometabolism And Nutrition)
  Member of the French Society of Endocrinology, the French Society of Cardiology, and the Editorial Board of 10 scientific French journals.
Past Position
1991-1999 Member of the Ethic Committee of the Pitié-Salpétrière hospital
2005 Responsible for the preparation of the French National Guidelines (treatment of dyslipidemia 2005)
2005-2007 President of the French Society of Atherosclerosis

He wrote 5 books and more than 700 papers of which more than 250 are in peer-reviewed Anglo-Saxon reviews.

Example of Research with hypolipidemic/antiatherosclerotic agents

Principal Investigator: torcetrapib and EIM in FH/combined hyperlipidemia, TAK 475 in FH patients, Colestagel in FH patients, Atorvastatin and ezetimibe in type II a dyslipidémie, daraplabib in stable CHD, Nicotinic and laropriprant in dyslipidemic patients, PI for three studies with PCSK inhibitor…

Example of publications

Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation. 2003, 107 (25): 3124-8

Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, Kontush A. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004; 89(10):4963-71.

Bruckert E, Verpilleux MP, Dejager S, Isaacsohn J. Comparison of efficacy and safety assessment of fluvastatin in patients <65 years versus > or =65 years of age. Am J Cardiol. 2005;96(8):1142-8.

Bruckert E, Baccara-Dinet, McCoy F, Chapamn MJ. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin. 2005;21(12):1927-34.

Bruckert E, Hayem G, Dejager S, Yau C, Begaud B, Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients -The PRIMO Study. Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14.

Hansel B, Kontush A, Giral P, Bonnefont-Rousselot D Chapman MJ, Bruckert E One third of the variability in HDL-cholesterol level in a large dyslipidaemic population is predicted by age, sex and triglyceridaemia: The Paris La Pitie Study. Curr Med Res Opin. 2006 Jun;22(6):1149-60.

Hansel B, Nicolle C, Lalanne F, Tondu F, Lassel T, Donazzolo Y, Ferrières J,  Krempf M, Schlienger JL, Verges B, Chapman MJ, Bruckert E. Effect of low-fat, fermented milk enriched with plant sterols on serum lipid profile and oxidative stress in moderate hypercholesterolemia. Am J Clin Nutr. 2007 Sep;86(3):790-6.

Baccara-Dinet M, Bruckert E. Are physicians able to identify high-risk abdominally obese individuals? Analysis from the pan-European Survey of HDL-cholesterol. Curr Med Res Opin. 2007;23(8):2005-8. Chiche F, Jublanc C, Coudert M, Carreau V, Kahn JF, Bruckert E. Hypothyroidism is not associated with increased carotid atherosclerosis when cardiovascular risk factors are accounted for in hyperlipidemic patients. Atherosclerosis. 2008 Jun 21.

Linares CL, Pelletier AL, Czernichow S, Vergnaud AC, Bonnefont-Rousselot D,Levy P, Ruszniewski P, Bruckert E. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas. 2008;37(1):13-2. Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard Bagnis C. Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med. 2008;121(5):426-32.

Hansel B, Thomas F, Pannier B, Bean K, Kontush A, Chapman MJ, Guize L, Bruckert E. Relationship between alcohol intake, health and social status and cardiovascular risk factors in the urban Paris-Ile-De-France Cohort: is the cardioprotective action of alcohol a myth? Eur J Clin Nutr. 2010;64(6):561-8.

Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210(2):353-61.
Carreau V, Girardet JP, Bruckert E. Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability Paediatr Drugs. 2011 Aug 1;13(4):267-75.

Cariou B, Zaïr Y, Staels B, Bruckert E. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism Diabetes

Fournier T, Bruckert E, Czernichow S, Paulmyer A, Poulain JP. The THEMA study: a sociodemographic survey of hypercholesterolaemic individuals. J Hum Nutr Diet. 2011 Dec;24(6):572-81.